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Background and purpose: A prostamide analogue, bimatoprost, has been shown to be effective in reducing intraocular
pressure, but its precise mechanism of action remains unclear. Hence, to elucidate the molecular mechanisms of this effect of
bimatoprost, we focused on pharmacologically characterizing prostaglandin FP receptor (FP) and FP receptor variant (altFP)
complexes.
Experimental approach: FP receptor mRNA variants were identified by reverse transcription-polymerase chain reaction. The
FP-altFP4 heterodimers were established in HEK293/EBNA cells co-expressing FP and altFP4 receptor variants. A fluorometric
imaging plate reader was used to study Ca
2þ mobilization. Upregulation of cysteine-rich angiogenic protein 61 (Cyr61) mRNA
was measured by Northern blot analysis, and phosphorylation of myosin light chain (MLC) by western analysis.
Key results: Six splicing variants of FP receptor mRNA were identified in human ocular tissues. Immunoprecipitation confirmed
that the FP receptor is dimerized with altFP4 receptors in HEK293/EBNA cells co-expressing FP and altFP4 receptors. In the
studies of the kinetic profile for Ca
2þ mobilization, prostaglandin F2a (PGF2a) elicited a rapid increase in intracellular Ca
2þ
followed by a steady state phase. In contrast, bimatoprost elicited an immediate increase in intracellular Ca
2þ followed by a
second phase. The prostamide antagonist, AGN211335, selectively and dose-dependently inhibited the bimatoprost-initiated
second phase of Ca
2þ mobilization, Cyr61 mRNA upregulation and MLC phosphorylation, but did not block the action of
PGF2a.
Conclusion and implications: Bimatoprost lacks effects on the FP receptor but may interact with the FP-altFP receptor
heterodimer to induce alterations in second messenger signalling. Hence, FP-altFP complexes may represent the underlying
basis of bimatoprost pharmacology.
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Introduction
Prostaglandin F2a (PGF2a) is a product of cyclooxygenase-
catalysed metabolism of arachidonic acid (Smith et al.,
1991). It has been identified to be an endogenous ligand of
prostaglandin FP receptors. Activation of FP receptors
initiated by ligand binding triggers Gaq protein-coupled
mechanisms involving Ca
2þ signalling, IP3 turnover and
activation of protein kinase C (Toh et al., 1995). PGF2a has
diverse physiological actions that include causing smooth
muscle contraction (Horton and Poyser, 1976), stimulating
DNA synthesis and cell proliferation, and cardiac myocyte
hypertrophy (Adams et al., 1996). Importantly, PGF2a
analogues have been used clinically to reduce ocular
hypertension (Woodward et al., 1993). Although the precise
mechanisms involved remain unclear, the effects of PGF2a
analogues on intraocular pressure (IOP) principally involve
an increase in uveoscleral outflow of aqueous humor. These
events involve secretion of metalloproteinases by ciliary
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www.brjpharmacol.orgsmooth muscle cells and remodelling of the extracellular
matrix with a resultant widening of intermuscular spaces
(Gaton et al., 2001; Weinreb and Lindsey, 2002; Richter et al.,
2003).
In contrast to prostaglandin F2a, prostamides (prosta-
glandin ethanolamides) were recently identified as a new
class of compounds that was formed from anandamide via
metabolic transformation catalysed by cyclooxygenase-2
(Yu et al., 1997; Burstein et al., 2000; Kozak et al., 2001;
Koda et al., 2003). Although their physiological actions have
not been fully investigated, a synthetic prostamide analogue
(bimatoprost) has been shown to be very effective in
reducing IOP by increasing both uveosceral and trabecular
outflow of aqueous humor (Woodward et al., 2001). The
activities of prostamides as endogenous ligands at prosta-
glandin receptor(s) have been investigated, but have been
shown to exert no meaningful activity (Berglund et al., 1999;
Woodward et al., 2001; Ross et al., 2002; Matias et al., 2004).
Studies on their metabolic rate clearly demonstrate that
prostamides and their synthetic analogue bimatoprost exert
their in vitro pharmacological effects (Matias et al., 2004) and
ocular hypotensive effects as the intact molecule (Woodward
et al., 2003). Experimental evidence suggests that prosta-
mides may act as endogenous ligands at their own receptors
(prostamide receptors) (Woodward et al., 2001, 2003; Matias
et al., 2004). Nevertheless, prostamide activity has not, so far,
been demonstrated in the absence of FP receptor activity.
However, results from studies on FP-knockout mice have
shown that the effects of bimatoprost on IOP are dependent
on an intact FP receptor gene (Crowston et al., 2005; Ota
et al., 2005); a single application of bimatoprost did not
reduce IOP in FP receptor knockout mice, indicating that FP
signalling is required for the early IOP response to bimato-
prost. This raised the possibility that bimatoprost may
interact with FP receptor gene products, such as spliced
variants of the FP receptor or FP receptor complexes, such as
FP receptor dimerizing or oligomerizing with FP spliced
variants or other receptors. It seemed reasonable, therefore,
to investigate newly discovered alternative splicing variants
of FP receptor mRNA for their potential to interact with
bimatoprost.
Methods
Total RNA isolation
Human eyes were obtained from the National Disease
Research Interchange (NDRI, Philadelphia, USA). These eyes
were hemisected along the ora serata to expose the posterior
chamber of the anterior segment. After the lens had been
removed by clipping the zonules, the ciliary body was peeled
away from the sclera and placed in ice-cold phosphate-
buffered saline.
Total RNA was isolated from human ciliary bodies and
human embryonic kidney 293/Epstein–Barr nuclear antigen
(HEK293/EBNA) cell lines using RNeasy Kit (Qiagen Inc.,
Valencia, CA, USA), according to the manufacturer’s instruc-
tion. RNA concentrations were determined by u.v. spectro-
photometry (Beckman DU640) at 260nm, and stored
at –801C.
Reverse transcription-polymerase chain reaction
Using 2mg of human total RNA, first-strand cDNA was
synthesized by SuperScript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). Samples, 20mL, containing 2mgo f
RNA, 100ng random primers and 50U reverse transcriptase
were incubated at 421C for 50min and terminated by 751C
for 15min.
The PCR buffer contained 40mM Tricine-KOH (pH 9.2),
15mM KOAc, 3.5mM Mg(OAc)2, 0.2mM of each dNTP, 0.2mM
upstream primer (p1: 50-tgcaatgcaatcacaggaatt-30) and down-
stream primer (p2: 50-cactccacagcattgactgg-30), and 1U
Advantage cDNA polymerase in a final volume of 50mL.
After an initial incubation for 5min at 941C, samples were
subjected to 35 cycles of 30s at 941C, 30s at 581C and 30s at
721C in a PE9700 thermal cycler.
The PCR products were isolated from 1.5% low-melting
agarose gel and subcloned into PCR II TOPO vector
(Invitrogen). Sequence analysis was performed by Sequetech
(Mountain View, CA, USA). Sequence alignments and
analysis were done using the National Center for Biotech-
nology Information database.
Subcloning and plasmid transfection
Full-length FP and alternative splicing variant of prostaglan-
din FP receptor (altFP) receptor cDNAs were isolated and
subcloned into retrovirus vector (Invitrogen). The plasmids
were designated QhFP-wt and QhFP-alt. QhFP-wt or QhFP-alt
were transfected into GP2-293 packaging cells. After 72h,
the supernatants containing virus were harvested and
centrifuged at 800g for 15min to remove cell debris. Virus
stock was titrated and stored at  801C. HEK293/EBNA cells
were grown in 6-cm dishes containing Dulbecco’s modified
Eagle’s medium with 10% fetal bovine serum. The cells were
infected with QhFP-wt or QhFP-alt, or co-infected with both
QhFP-wt and QhFP-alt in equal amounts of virus. After 24h
of infection, the virus-containing medium was removed and
replaced with fresh medium containing hygromycin for cell
clone selection. Hygromycin-resistant colonies were ampli-
fied and screened for expression of FP and altFP receptors.
The established cell lines were maintained in the same media
as the parental lines.
Epitope tagging of FP receptors and altFP receptors
Wild-type FP and altFP receptors were tagged at their amino
termini with either two repeats of haemagglutinin (HA)
nonapeptide (YPYDVPDYA) separated by a Gly residue or
with two repeats of a Flag sequence (DYKDDDDK), also
separated by a Gly residue. Because the FP receptors
containing two Flag epitopes or HA epitopes at the amino
terminus may not localize to the cell membrane (Fujino
et al., 2000), we introduced a prolactin signal peptide
preceding the Flag sequence to create Pro-Flag-FP and
preceding the HA sequence to create Pro-HA-altFP, according
to methods previously described (Kolodziej and Young,
1991). Pro-Flag-FP or Pro-HA-altFP cDNA encoded the amino
terminus MDSKGSSQKGSRLL LLLVVSNLLLCQGVVS/DYKD
DDKy or MDSKGSSQKGSRLLLLLVVSNLLLCQ GVVS/
YPYDVPD YAyrepresenting the prolactin signal peptide,
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The prolactin signal peptide was then cleaved by signal
peptidase after expression. All of the tagged FP or altFP
receptors were subcloned into lentivirus expression vector to
create Lenti-Pro-Flag-FP and Lenti-Pro-HA-altFP expression
plasmids. All of the plasmids were transfected into 293FT
packaging cell lines. After 48h transfection, the virus
containing cell medium was collected, titered and stored at
–801C. HEK293/EBNA cells were grown in 6-cm dishes
containing Dulbecco’s modified Eagle’s medium with 10%
fetal bovine serum. The cells were infected with an equal
amount of virus. After 24h of infection, the virus-containing
medium was removed and replaced with fresh medium
containing blasticidin for cell clone selection. Blasticidin-
resistant colonies were amplified and screened for expression
of Flag-FP and HA-altFP receptors. The established cell lines
were maintained in the same medium as the parental lines.
Northern blot analysis
Total RNA (10mg) was denatured at 651C in RNA loading
buffer (Ambion Inc., Austin, TX, USA) for 15min and
separated on 1.2% agarose gels containing 0.66 M formalde-
hyde. RNA loading was assessed by ethidium bromide
staining of 28S and 18S ribosomal RNA bands. The relative
intensities of 28S and 18S ribosomal RNA bands were used as
internal controls to normalize the hybridizations. Human
1.4-kb Cyr61 (þ60 to þ1459; GenBank accession no.
AF003594) gene-specific DNA fragment was radiolabelled
using an [a-
32P]-dCTP and Klenow (Ambion Inc.). The blots
were hybridized with the gene-specific probes in 50%
formamide, 4  SSC, 1  Denhardt’s solution, 50mM sodium
phosphate (pH 7.0), 1% sodium dodecyl sulphate (SDS),
50mgmL
 1 yeast tRNA and 0.5mgmL
 1 sodium pyropho-
sphate at 421C overnight and washed with SSC and 0.1%
SDS twice at 421C and with 0.1  SSC and 0.1% SDS twice at
421C. The hybridized blots were exposed to phosphor
screens, and the exposed screens were analysed in a
PhosphorImager (Amersham Biosciences, Pittsburgh, PA,
USA).
Immunoprecipitation and western blotting
HEK293/EBNA cells were cultured in six-well plates. The
confluent cells were harvested, washed and lysed in ice-cold
lysis buffer containing 150mM NaCl, 50mM Tris HCl (pH
8.0), 1mM EDTA, 1% Triton X-100, 10mM NaF, 10mM
sodium pyrophosphate, 100mM sodium orthovanadate plus
protease inhibitor mixture. The cell lysates were centrifuged
at 14000g,a t41C, for 10min. For immunoprecipitation, the
supernatant fractions were collected and then incubated at
41C with HA11 (HA antibody) for 15h. The incubation was
continued for another 1h in the presence of 50mL of a 1:1
slurry of protein G agarose (Pierce, Rockford, IL, USA) at 41C.
The beads were washed three times with lysis buffer,
Laemmli sample buffer was added and the samples were
boiled for 5min and centrifuged at 12000g for 10min. The
supernatant fractions were subjected to western blot. In
general, the supernatant fraction from immunoprecipitation
or from cell lysates of transfected HEK293/EBNA cells were
collected and electrophoresed on 10% SDS-polyacrylamide
(SDS-PAGE) gels. Proteins were transferred to polyvinylidene
fluoride membrane, and the blots were incubated with a
1:1000 dilution of a monoclonal HA11 or anti-Flag M2
antibody for 1h at room temperature with rotation. The
blots were washed three times and incubated for 1h at room
temperature with a 1:5000 dilution of a goat anti-mouse
secondary antibody (Bio-Rad, Hercules, CA, USA) conjugated
with horseradish peroxidase. After being washed three times,
immunoreactivity of the samples was detected using an
immune-star HRP developer system (Bio-Rad).
MLC phosphorylation
HEK293/EBNA cells were cultured in 10-cm plates. The cells
were deprived of nutrients in Opti-MEM for 24h before
being pretreated with 2-[3-(5-fluoro-2-propylcarbamoyl-
methoxybenzyl)-7-oxabicyclo[2.2.1]hept-2-yloxazole-4-carbo-
xylic acid (4-cyclohexylbutyl) amide (AGN211335) for
15min, followed by treatment with PGF2a or bimatoprost
for 30min. The cell lysates were boiled for 5min and
centrifuged at 12000g for 10min. The supernatant fractions
were collected and electrophoresed on 10% SDS-PAGE gels.
Proteins were transferred to polyvinylidene fluoride mem-
brane, and the blots were incubated with a 1:1000 dilution of
a phosphorylated myosin light chain (MLC) antibody or
MLC antibody for 16h at 41C with rotation. The blots were
washed three times and incubated for 1h at room tempera-
ture with a 1:3000 dilution of a goat anti-rabbit secondary
antibody (Bio-Rad) conjugated with horseradish peroxidase.
After being washed three times, immunoreactivity of the
samples was detected using an immune-star HRP developer
system (Bio-Rad).
Calcium signal studies using a FLIPR instrument
HEK293/EBNA cells were seeded at a density of 50000 cells
per well in Biocoat poly-D-lysine-coated black-well, clear-
bottom 96-well plates (Becton-Dickinson) and allowed to
attach overnight. Before the assay, the cells were washed
twice with Hank’s balanced salt solution-HEPES buffer
(without bicarbonate and phenol red, 20mM HEPES, pH
7.4) using a Lab Systems Cellwash plate washer. After being
subjected to 45min of dye loading (fluo-4 AM, 2mM) in the
dark at 371C in 5% CO2 humidified atmosphere, the plates
were washed three times with Hank’s balanced salt solution-
HEPES buffer to remove excess dye leaving 100mL buffer in
each well. Plates were equilibrated to 371C for 3min prior to
processing within the fluorometric imaging plate reader
(FLIPR). The peak increase in fluorescence counts was
recorded for each well. All data points were determined in
triplicate. Mock-transfected cells (transfected with empty
plasmid) were screened in parallel with FP- and alternative
FP-co-transfected cells.
Prostamide antagonist
pA2 determination. The methods used to study the effects of
antagonists of prostamide F2a on bimatoprost-induced feline
iridial stimulation and associated data analysis were identical
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2007; Woodward et al., 2007). Briefly, feline iridial tissue
specimens were mounted vertically under 50–100mg ten-
sion in 10mL jacketed organ baths. These contained Krebs
solution maintained at 371C and gassed with 95% O2 and
5% CO2. Measurement of contractile activity was by means
of force displacement transducers and was recorded on a
polygraph chart recorder. After a 1-h equilibration period,
vehicle and antagonist (AGN211335) were administered
30min before the agonist dose–response curve was
constructed. Agonist concentration–response curves were
compared in the presence and absence of graded doses of
antagonist (AGN211335). PGF2a (10
 7 M) was used at the
beginning and end of each dose–response experiment as a
reference compound. The pA2 value for AGN211335 was
obtained by plotting log10 concentration–response-1 vs
log10[antagonist] according to the method of Arunlakshana
and Schild (1959), using Graphpad Prism 4 software (Wood-
ward et al., 2007). Feline iridial experiments were performed
by Covance Inc. (Madison, WI, USA).
Human recombinant prostaglandin receptors. Studies on human
recombinant prostaglandin receptors were as previously
described (Woodward et al., 2003; Matias et al., 2004). These
involved Ca
2þ signal studies and the use of a FLIPR
instrument. The use of chimeric G protein cDNAs allowed
responses to Gs- and Gi-coupled receptors to be measured as
aC a
2þ signal. Thus, prostaglandin DP, EP2 and EP4 receptor
cDNAs were co-transfected with chimeric Gqs cDNA, and EP3
receptor cDNA was co-transfected with chimeric Gqi cDNA
(Molecular Devices, Sunnyvale, CA, USA), each containing a
haemagluttanin (HA) epitope to detect protein expression.
Stable transfection in HEK293/EBNA cells was achieved using
the same vectors and Fugene 6 method as previously
described. Stable transfectants were selected according to
hygromycin resistance. FLIPR studies were performed as
described in the previous section. AGN211335, 3 10
 5 M,
was given as a 10min pretreatment, vehicle control wells
were pretreated with an equal volume of ethanol. Agonists
used for each receptor are listed as follows: BW245C for DP;
PGE2 for EP1–4; PGF2a for FP; carbaprostacyclin for IP and
U-46619 for IP receptors. The peak fluorescence change in
each well containing the drug was expressed relative to the
controls. No activity was observed at DP1–2,E P 1–4,F Po rI P
receptors for 3 10
 5 M AGN211335. AGN211335 was a TP
antagonist with a kb of 101nM.
Activity at DP2 (CRTH2) receptors was determined by
externally using a proprietary FLIPR-based assay (GPCRPro-
filer, Millipore Corp., St Charles, MO, USA). The experi-
mental conditions were identical to those employed at
Allergan Inc.; PGD2 was used as an agonist in this assay.
AGN211335, 3 10
 5 M, was found to have no activity at the
DP2 receptor.
Drugs
AGN211335 was synthesized by Selcia Ltd (Ongar, Essex,
UK). Bimatoprost and PGF2a were purchased from Cayman
Chemical Co. (Ann Arbor, MI, USA). All stock solutions were
prepared in ethanol. Screening methods for the prostamide
antagonist, AGN211335, were as previously described
(Woodward et al., 2007).
Figure 1 Reverse transcription-polymerase chain reaction analysis of the FP receptor gene in human ciliary bodies. (a) The location of PCR
products of the correct size for known wild-type FP receptor, abbreviated as WT-FP, and FP receptor variants, abbreviated as AltFP, are
indicated by arrows. Sequencing analysis showed that the band of altFP contains multiple FP receptor variants. (b) The black bars represent the
coding sequence for the wild-type FP receptor. There are five additional exons generated by mRNA alternative splicing, located between exon
2 and exon 3 and indicated as exon A, exon B, exon C, exon D and exon E.
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abbreviated as FP WT; the FP receptor variants are abbreviated as alt-1, alt-2, alt-3, alt-4, alt-5 and alt-6. An arrow in the carboxyl terminal area
of the polypeptides indicates the location where the wild-type human FP receptor and the FP receptor variants alt-1 through alt-6 begin to
diverge.
Figure 3 Physical interaction of FP and altFP4 receptors in HEK293/
EBNA cells co-expressing FP and altFP receptors. (a) Membrane
preparations from control HEK293/EBNA cells (lane 1) and cells
stably transfected with HA-altFP4 (lane 2) and cells stably co-
transfected with Flag-FP and HA-altFP4 (lane 3) were resolved by
10% sodium dodecyl sulphate-polyacrylamide (SDS-PAGE), trans-
ferred onto a polyvinylidene fluoride membrane and probed with
anti-HA antibody, HA11. Arrows indicate altFP4 receptor or altFP4
homodimer or FP-altFP4 heterodimer. (b) FP receptors were
immunoprecipitated (IP) with anti-HA antibody, from HEK293/EBNA
cells transfected with Flag-FP (lane 1), HA-altFP4 (lane 2) or both
(lane 3). Proteins were resolved on SDS-PAGE and probed with anti-
Flag antibody in immunoblot analyses. Arrows denote FP receptors.
HC represents heavy chain. LC represents light chain. HA,
haemagglutinin.
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Data are expressed as mean±s.d. A significant difference
between treatments was assessed by the one-way ANOVA,
followed by a Bonferroni’s post test procedure for multiple
comparisons. Differences between treatments were consid-
ered to be significant if Po0.05. All statistical values were
calculated using Graphpad Prism 4 software (GraphPad,
San Diego, CA, USA).
Results
Identification of prostaglandin FP receptor variants in human eyes
To identify potential alternative mRNA splicing variants of
the human FP receptor, reverse transcription-polymerase
chain reaction analyses were performed using human ciliary
body cDNA libraries and two FP-specific primers, p1, which
is complementary to FP exon 2 sequence, and p2, which is
complementary to FP exon 3 sequence. PCR products were
subcloned and sequenced (Figure 1a). Sequence analysis
showed that there are five additional exons between exon 2
and exon 3 (Figure 1b). The human FP receptor gene
contains three exons. The coding region of the FP receptor
is located within exon 2 and exon 3. An insertion of the
additional exon in the coding region causes frame shifts that
lead to encode C terminus-truncated FP receptors (altFPs).
Figure 2 shows the deduced amino-acid sequences of human
FP (FP) and FP variants (altFPs). The FP and altFPs are
identical up to amino acid 266 (leucine-266), at which point
there is an insertion of additional exon A, exon B, exon C
and exon E to form altFP1, altFP2, altFP4 and altFP5,
respectively, and an insertion of two additional exons, exon
A and B to form altFP3 and two additional exons, exon D and
exon E to form altFP6. The amino-acid sequences of altFPs
diverge from those of FP at leucine 266, which is close to the
predicted carboxyl terminal end of TM6. For the human
wild-type FP receptor, there are a total of 93 amino acids
downstream of leucine-266, which constitute the third
extracellular loop ( 19 amino acids), TM7 ( 22 amino
acids) and the intracellular carboxyl terminus ( 52 amino
acids). A hydropathic profile analysis of FP and altFPs shows
that all altFPs do not have a seventh TM domain and that
its carboxyl terminus is extracellular. All altFPs were stably
expressed in HEK293/EBNA cell lines. Cells expressing
alternative FP receptor mRNA splicing variants were screened
with FP ligands and bimatoprost using the FLIPR assay and
could not be activated by 10mM PGF2a or bimatoprost (data
not shown). This is entirely consistent with data from a
previous study demonstrating that the first alternative
variant of human FP receptor RNA (Vielhauer et al., 2004)
is not the prostamide receptor. We thought that altFPs, as
six-domain receptors, form dimers with FP receptors and
function as regulators of the FP receptor. The next experi-
ments were done to determine whether altFPs could form
dimers with FP and to characterize their functions. Initial
screening of the HEK293/EBNA cells co-transfected FP with
each of altFPs (altFP1 and altFP6) showed that the
co-transfected HEK293/EBNA cells responded to bimatoprost
with a similar CA
2þ mobilization profile to that of Ca
2þ
mobilization. As the longer C terminus of altFP4 provides a
better prognosis for, perhaps, eventually designing a specific
antibody to this isoform, we focused on characterizing the
pharmacology of FP and its interaction with the altFP4
receptor heterodimer in the following studies.
Physical interactions between FP and altFP4 receptors
We initially developed stable cell lines of HEK293/EBNA cells
expressing epitope-tagged FP and altFP receptors because this
cell type has a high transfection efficiency and wide
application in studies involving G protein-coupled receptors.
Infection of HEK293/EBNA cells with Lenti-Pro-HA-altFP4 or
Figure 4 Ca
2þ signalling of HEK293/EBNA cells co-expressing FP and altFP4 receptors following prostaglandin F2a (PGF2a) and bimatoprost
treatments. (a) Real-time fluorescence traces were recorded by fluorometric imaging plate reader (FLIPR) in HEK293/EBNA cells co-expressing
FP and altFP4 receptors following PGF2a (10
 7 M) or bimatoprost (10
 7 M) treatment. (I) After recording baseline for 300s, 10
 7 M PGF2a was
added and recorded for additional 600s. (II) After recording baseline for 300s, 10
 7 M bimatoprost was added and recorded for additional
600s. (b) Real-time fluorescence traces were recorded by FLIPR following PGF2a (10
 7 M, I) or bimatoprost (10
 7 M, II) in HEK293/EBNA cells
expressing wt-FP receptor. Real-time fluorescence traces were recorded immediately following PGF2a (10
 7 M) or bimatoprost (10
 7 M)
treatment. (c) Real-time fluorescence traces were recorded by FLIPR in HEK293/EBNA cells expressing altFP4 receptor following PGF2a (10
 7 M,
I) or bimatoprost (10
 7 M, II) treatment for 600s. (d) Real-time fluorescence traces were recorded by FLIPR in HEK293/EBNA cells co-expressing
FP and altFP4 receptors following PGF2a (10
 7 M, I) or bimatoprost (10
 7 M, II) treatment in Ca
2þ-free buffer for 600s. (e) The first peak
increase of fluorescence counts was recorded in each treatment (aI–dII). The data represent mean±s.d. of three independent experiments.
***Po0.01 versus PGF2a treatment (aI).
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with Lenti-Pro-HA-altFP4 and Lenti-Pro-Flag-FP, with an
equal amount of virus, resulted in the appearance of multiple
bands on immunoblots that were immunoreactive to HA11,
a mouse monoclonal anti-HA antibody (Figure 3a, lanes 2
and 3). These bands were not present in the control cells
Figure 5 Continued.
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FP receptor proteins. Figure 3a shows that the molecular
weights of the bottom bands in both lane 2 and lane 3 were
33kDa, which is very close to the calculated molecular mass
of epitope-tagged altFP4 receptor, 34kDa. Higher molecular
weight top bands were also observed, a 66kDa in lane 2,
which is close to the calculated molecular weight mass of
altFP4 homodimer, 68kDa, and a 75kDa in lane 3, which is
very close to the calculated molecular weight mass of FP-
altFP4 heterodimer, 74kDa, suggesting that altFP4 receptors
form homodimers (Figure 3a, lane 2) and that FP and altFP4
co-transfection (Figure 3a, lane 3) also formed heterodimers
(FP molecular weight is higher than the altFP4 receptor).
To clarify whether the higher molecular weight band
(75kDa; Figure 3a, lane 3) was derived from receptor
heterodimerization or association with other unknown
proteins, we conducted differential immunoprecipitation
in which two different epitope-tagged receptors, HA-altFP4
and Flag-FP, were co-expressed and subjected to immuno-
precipitation with anti-HA antibody, HA11, against HA-tag
and then resolved on SDS-PAGE and immunoblotted with
anti-Flag M2 an antibody against the Flag-tag FP receptor. As
shown in Figure 3b (lane 3) when Flag-FP and HA-altFP4
receptors were co-expressed in HEK293/EBNA cells, Flag-FP
receptors were clearly present in HA antibody-derived
immunoprecipitates (Figure 3b, lane 3), which further
confirms that the 75-kDa band (Figure 3a, lane 3) is an
FP-altFP4 heterodimer. When HEK293/EBNA cells were
separately transfected with Flag-FP or HA-altFP4 receptors,
no Flag-tagged receptor (Flag-FP) was immunoprecipitated
with HA antibody (Figure 3b, lane 1), and no HA-tagged
receptor (HA-altFP4) was immunoblotted with Flag antibody
(Figure 3b, lane 2). Again, the Flag-tag FP receptor was
seen only in the co-transfected HEK293/EBNA cells
(Figure 3b, lane 3).
Functional studies of FP receptor and altFP4 receptor dimeriza-
tion. To investigate the effects of PGF2a and bimatoprost on
FP-altFP4 receptor heterodimer, we performed Ca
2þ mobili-
zation studies on HEK293/EBNA cells co-expressing epitope-
tagged HA-altFP4 and Flag-FP and HEK293/EBNA cells
co-expressing FP and altFP4 receptors, using a FLIPR.
Both HEK293/EBNA cell lines showed exactly the same
kinetic profile for Ca
2þ mobilization induced by PGF2a or
bimatoprost, indicating that epitopes contained in the amino
terminus of the FP and altFP4 receptors did not disrupt the
expression or functions of these receptors. In this study, we
used HEK293/EBNA cell lines co-expressing FP and altFP4,
expressing only FP and only altFP4 as cell models. Figure 4
shows that PGF2a,1 0
 7 M, activated FP-altFP4 (Figure 4aI)
and the FP receptor (Figure 4bI). There was no difference
between only FP and FP-altFP4 in response to PGF2a in terms
of first peak of fluorescence counts and kinetic profiles. Both
PGF2a and bimatoprost at 10
 7 M activated the FP-altFP4
receptor heterodimer; the first peak of fluorescence counts
for bimatoprost treatment were very close to those of PGF2a
(Figure 4aI and II). The kinetic profiles of real-time
fluorescence traces for PGF2a and bimatoprost treatments
were different. PGF2a elicited a robust and rapid increase in
intracellular Ca
2þ concentration followed by a steady-state
phase within the time course of the experiment (600s, count
from the initiation of a rapid Ca
2þ increase) (Figure 4aI). In
contrast, bimatoprost elicited an immediate and robust
increase in intracellular Ca
2þ concentration followed by a
second phase Ca
2þ wave within the time course of the
experiment (600s) (Figure 4aII). This observation accords
well with the results obtained in Ca
2þ signalling studies in
cat iris sphincter cells stimulated by bimatoprost. Bimato-
prost was shown to elicit an immediate increase in
intracellular Ca
2þ concentration followed by a second
Ca
2þ wave, suggesting the existence of a native FP-altFP4
receptor heterodimer in cat iris sphincter cells (Spada et al.,
2005). Although PGF2a markedly stimulated the wild-type FP
receptor, bimatoprost produced not more than a residual
effect (Figure 4bI and II). Neither PGF2a nor bimatoprost
activated the altFP4 receptor (Figure 4cI and II). To
Figure 5 The prostamide-selective antagonist, AGN211335, inhibited bimatoprost-initiated second-phase Ca
2þ mobilization in HEK293/
EBNA cells co-expressing FP and altFP4 receptors. Real-time fluorescence traces were recorded by fluorometric imaging plate reader
instrumentation in HEK293/EBNA cells co-expressing FP and altFP4 receptors following the antagonist protocol. (a) HEK293/EBNA cells co-
expressing FP and altFP4 receptor pretreated with buffer (I), AGN211335 at 10
 6 M (II), AGN211335 at 10
 7 M (III) and AGN211335 at 10
 8 M
(IV) for 300s, immediately followed by 10
 7 M prostaglandin F2a (PGF2a) treatment for 600s. (b) HEK293/EBNA cells co-expressing FP and
altFP4 receptors pretreated with buffer (I), AGN211335 at 10
 6 M (II), AGN211335 at 10
 7 M (III) and AGN211335 at 10
 8 M (IV) for 300s,
immediately followed by 10
 7 M bimatoprost treatment for 600s. (c) The first peak increase of fluorescence counts was recorded for each
treatment (aI–bIV). The data represent mean±s.d. of three independent experiments. No significant differences between treatments were
observed. (d) The second peak increase of fluorescence counts was recorded after bimatoprost treatment (bI–IV). The data represent
mean±s.d. of three independent experiments. ***Po0.01 versus bimatoprost alone (bI).
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2þ
signal initiated by bimatoprost, Ca
2þ-free buffer was used in
the FLIPR assay. Both PGF2a and bimatoprost elicited a rapid
increase in intracellular Ca
2þ concentration followed by an
immediate return to baseline (Figure 4dI and II), suggesting
that the bimatoprost-initiated second-phase Ca
2þ mobiliza-
tion may be attributed to store-operated Ca
2þ influx. The
data are summarized in Figure 4e. To determine whether the
bimatoprost-initiated second-phase Ca
2þ mobilization is
due to Ca
2þ release from a second intracellular Ca
2þ store,
thapsigargin, a Ca
2þ-ATPase inhibitor, was used to deplete
the endoplasmic reticulum Ca
2þ store in the cells before
bimatoprost treatment. The experiments showed that there
is no further Ca
2þ release upon bimatoprost treatment after
endoplasmic reticulum Ca
2þ stores were completely de-
pleted, suggesting that bimatoprost-initiated second-phase
Ca
2þ mobilization may not be due to the release of Ca
2þ
from a second intracellular Ca
2þ store (data not shown).
Figure 6 Northern blot analysis of Cyr61 gene expression following prostaglandin F2a (PGF2a) and bimatoprost treatment. (a) HEK293/EBNA
cells co-expressing FP and altFP4 receptors were pretreated with 10
 6–10
 8 M AGN211335 for 15min (a, top and bottom panels, lanes 3–5)
and with 10
 7 M PGF2a for 1h (a, top panel, lanes 2–5) or with 10
 7 M bimatoprost for 1h (a, bottom panel, lanes 2–5). Arrows indicate Cyr61
mRNA levels. (a, right panels) The data represent mean±s.d. of three independent densitometric experiments. **Po0.01 versus control;
***Po0.01 versus bimatoprost alone. The intensities of the 18S rRNA bands were used to normalize the RNA-loading differences. (b) HEK293/
EBNA cells expressing FP receptor were pretreated with 10
 6M AGN211335 for 15min (lanes 3 and 6) and with 10
 7 M PGF2a for 1h (lanes 2
and 3) or with 10
 7 M bimatoprost for 1h (lanes 5 and 6) or with 2mM thapsigargin for 15min (lane 7). Arrows indicate Cyr61 mRNA levels. (b,
right panel) The data represent mean±s.d. of three independent densitometric experiments. **Po0.01 versus control. The intensities of the
18S rRNA bands were used to normalize the RNA-loading differences.
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selectively inhibited the bimatoprost-initiated second phase
of Ca
2þ mobilization in HEK293/EBNA cells co-expressing
FP and altFP4 receptors, in a dose-dependent manner (Figure
5bI–IV), but did
not block the steady-state phase of that induced by PGF2a
(Figure 5aI–IV). A summary of these data is shown in
Figure 5c and d.
To determine whether the prostamide antagonist selec-
tively blocks bimatoprost-induced biochemical signal cas-
cades, we used the Cyr61 factor and MLC as biochemical
signals to perform Cyr61 mRNA expression studies and MLC
phosphorylation studies. Cyr61 has been well-characterized
and regulates extracellular matrix remodelling through
activation of matrix metalloproteinases (Liang et al., 2003).
Phosphorylation of MLC causes ciliary muscle contraction
with a resultant widening of intermuscular spaces (Ansari
et al., 2003). Increases in uveoscleral outflow result from
extracellular matrix remodelling of the ciliary body and
widened intermuscular spaces. Both PGF2a and bimatoprost
induced Cyr61 mRNA upregulation and MLC phosphoryla-
tion in HEK293/EBNA cells co-expressing FP and altFP4
receptors (Figures 6a and 7a). Even though PGF2a induced
Cyr61 mRNA upregulation and MLC phosphorylation
in HEK293/EBNA cells expressing the wild-type FP
receptor, bimatoprost produced no effects (Figure 6b). The
prostamide antagonist, AGN211335, selectively blocked
both bimatoprost-induced Cyr61 mRNA upregulation and
bimatoprost-induced MLC phosphorylation in HEK293/EBNA
cells co-expressing FP and altFP4 receptors, but not those
induced by PGF2a (Figures 6a and 7a). We also investigated the
effects of thapsigargin, as it activates store-operated channels
independently of G protein-coupled receptors. However, it
failed to induce Cyr61 mRNA upregulation (Figure 6b),
indicating that induction of Cyr61 mRNA upregulation
requires more signal transduction pathways, possibly those
involving the activation of G12/13 and RhoA (Liang et al.,
2003). These data fit well with the prostamide antagonist
profile, which selectively inhibits bimatoprost-induced feline
iris contraction, but not that produced by PGF2a.
Figure 7 Effects of prostaglandin F2a (PGF2a) and bimatoprost on myosin light chain (MLC) phosphorylation. (a) HEK293/EBNA cells co-
expressing FP and altFP4 receptors were pretreated with 10
 6 M AGN211335 for 15min (lanes 2 and 5) and with 10
 7 M PGF2a for 30min
(lanes 2 and 3) or with 10
 7 M bimatoprost for 30min (lanes 5 and 6). Arrows indicate MLC phosphorylation. (a, right panel) The data
represent mean±s.d. of three independent experiments. **Po0.01 versus control; ***Po0.01 versus bimatoprost alone. The intensities of the
total MLC bands were used to normalize the protein-loading differences. (b) HEK293/EBNA cells expressing the FP receptor were pretreated
with 10
 6 M AGN211335 for 15min (lanes 2 and 5) and with 10
 7 M PGF2a for 30min (lanes 2 and 3) or with 10
 7 M bimatoprost for 30min
(lanes 5 and 6). Arrows indicate MLC phosphorylation. (b, right panel) The data represent mean±s.d. of three independent experiments.
**Po0.01 versus control. The intensities of the total MLC bands were used to normalize the protein-loading differences.
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AGN211335. The effects of graded doses of AGN211335
pretreatment on feline iridial contraction produced by PGF2a
and prostamide F2a are depicted in Figure 8. AGN211335,
over the dose range 3 10
 7 3 10
 5 M, did not have a
significant effect on the iridial response to PGF2a (Figure 8a).
In marked contrast, and at all the doses used, AGN211335
produced a dose-dependent rightward shift of the prosta-
mide dose–response curve (Figure 8b). Thus, in a single
preparation, AGN211335 selectively blocks the prostamide
effect without altering the response to PGF2a. As described in
a previous study (Woodward et al., 2007), the antagonist
effects were never totally surmounted by 10mM prostamide
F2a; this has been attributed to off-target activity for
prostamide F2a at prostanoid FP receptor in the feline iris
(Matias et al., 2004; Spada et al., 2005). The AGN211335
antagonism of the prostamide F2a was subjected to Schild
analysis, as previously described (Woodward et al., 2007).
AGN211335 appeared to be a competitive antagonist with a
pA2 of 7.50. Finally, bimatoprost stimulation of feline iridial
contraction did not occur in Ca
2þ-free medium (Figure 8c).
AGN211335 was screened for activity at other prosta-
glandin receptors using the full range of human recombi-
nant receptors. No activity was observed at DP1 2,E P 1–4,F P
or IP receptors for 3 10
 5 M AGN211335. AGN211335 is
also a TP antagonist, with a kb of 101nM, but is less potent as
a TP receptor antagonist than the prototype prostamide
antagonist AGN204396 (Woodward et al., 2007). As func-
tional TP receptors are not present in the feline iris
preparation, this activity of AGN211335 does not interfere
with the analysis of FP and prostamide receptor pharmacology.
Discussion
The pharmacology and physiological significance of trun-
cated prostanoid receptors lacking an intracellular carboxyl
terminus has remained obscure. Although transcripts for
Figure 8 Effect of graded doses of AGN211335 on contractions of the feline isolated iris. (a) Effect of AGN211335, 3 10
 7–3 10
 5 M,
compared to vehicle on responses produced by prostaglandin F2a (PGF2a). (b) Effect of the same concentrations of AGN211335, compared to
vehicle, on responses produced by prostamide F2a.( c) Effect of bimatoprost, in the absence and presence of Ca
2þ in the physiological buffer,
on the isolated iris. Values are mean±s.e.mean, n¼4.
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(Okuda-Ashitaka et al., 1996) receptors were found in tissues,
no ligand-dependent activation was observed (Okuda-Ashi-
taka et al., 1996; Vielhauer et al., 2004). Likewise, the FP
receptor variants described herein show no meaningful G
protein-coupled receptor-like activity. However, these novel
FP receptor mRNA splicing variants are capable of hetero-
dimerization with wild-type FP receptors. These heterodi-
mers are distinct from the component monomers in terms
of both ligand recognition and Ca
2þ signalling. For PGF2a,
wild-type FP and the FP-altFP4 heterodimer respond in an
identical manner with a Ca
2þ transient followed by an
elevated steady-state phase. These heterodimers differ from
wild-type FP receptors in that they appear highly responsive
to the prostamide analogue bimatoprost (Woodward et al.,
2003; Matias et al., 2004). Moreover, interaction with
bimatoprost results in a biphasic Ca
2þ signal composed of
a rapid transient response succeeded by secondary Ca
2þ
waves. The transient phase represents Ca
2þ release from
intracellular stores. The secondary phase appears to involve
Ca
2þ influx and is absent when extracellular Ca
2þ is
removed. The secondary phase of Ca
2þ signalling
is susceptible to the prostamide antagonist AGN211335.
This suggests that FP-altFP receptor heterodimerization may
represent the putative prostamide receptor (Gandolfi and
Cimino, 2003; Woodward et al., 2003, 2007; Matias et al., 2004).
There are a number of close correlations between the
FP-altFP recombinant receptor model and prostamide phar-
macology observed in cells, tissues and living animals. To
date, prostamide F2a and bimatoprost have been found to be
active only in cells and tissues that express functional
prostanoid FP receptors (Woodward et al., 2001, 2003,
2007; Liang et al., 2003; Richter et al., 2003; Matias et al.,
2004). This is consistent with the presence of FP-altFP
heterodimers, which are responsive to prostamides and are
indistinguishable from FP receptors with respect to PGF2a
effects. A close connection to the FP receptor gene is further
indicated by studies claiming that the ocular hypotensive
effect of bimatoprost is absent in -/-FP mice (Crowston et al.,
2005; Ota et al., 2005). Upregulation of Cyr61 appears to be a
common upstream event in the initiation of ciliary muscle
re-modelling and resultant increases in uveoscleral outflow,
which are common to ocular hypotensive prostamides, FP
and EP2 receptor agonists (Liang et al., 2003; Richter et al.,
2003). As human ciliary muscle cells are sensitive to
bimatoprost, mRNA for the newly discovered altFP variants
would be expected to be present in these cells, and this has
been shown to be the case.
The discovery of selective antagonists has been of para-
mount importance in defining prostamide pharmacology.
The prototypical prostamide antagonist AGN204396 was
described in 2007 (Woodward et al., 2007), but since then,
rapid progress has occurred. Second-generation prostamide
antagonists, such as AGN211334, which has been shown to
block bimatoprost activity in human eye perfusion model
(Wan et al., 2007) and AGN211335, are approximately 100
times more potent than their prototype. The susceptibility of
the bimatoprost-induced secondary Ca
2þ influx response in
FP-altFP heterodimer to blockade by AGN211335 applies to
all prostamide-sensitive preparations. The lack of inhibition
afforded by AGN211335 on PGF2a-induced Ca
2þ signalling
in the FP-altFP receptor model similarly applies to prosta-
mide-sensitive cells and tissues. Thus, AGN211335 dose-
dependently blocks the feline iridial response to prostamide
F2a but not to PGF2a. It is important to note that feline iridial
contraction is entirely dependent on extracellular Ca
2þ.
It follows that AGN211335 inhibition of the prostamide-
induced secondary Ca
2þ signals associated with FP-altFP
heterodimer also correlates with Ca
2þ-dependent contrac-
tion of feline iridial tissue. To date, there is no feline FP gene
structure available in a public database. It is not known if
altFPs are expressed in feline iridial tissue. As it is established
that the effects of prostamides and the prostamide antago-
nist AGN211335 in the FP-altFP4 receptor model correspond
closely to those in the feline iridial contractile response
model, it is reasonable for us to speculate that feline
iridial tissue may express FP-altFP heterodimers that are
sensitive to prostamide F2a and AGN211335. The mechanism
of the AGN211335-insensitive transient release of intra-
cellular Ca
2þ produced by bimatoprost is not readily
apparent. It appears that the FP-altFP4 heterodimer main-
tains responsiveness to PGF2a and acquires sensitivity to
prostamides, with a common initial Ca
2þ signalling path-
way, involving release of Ca
2þ from intracellular stores.
Thereafter, the Ca
2þ signalling pathways diverge, as re-
flected by subsequent phases that are pharmacologically and
qualitatively distinct. Antagonism of recombinant and
native prostamide-sensitive FP-altFP heterodimeric receptors
extends beyond Ca
2þ signalling and smooth muscle con-
traction. Bimatoprost-induced Cyr61 mRNA upregulation in
human ciliary smooth muscle cells is replicated in the FP-
altFP4 heterodimeric receptor model and, importantly, is
blocked by the prostamide antagonist AGN211335 (Liang
et al., 2003). Finally, bimatoprost-induced MLC phosphor-
ylation associated with FP-altFP4 heterodimeric receptors
was blocked by AGN211335. Again, in the case of both MLC
phosphorylation and Cyr61 upregulation, PGF2a effects were
not affected by pretreatment with the prostamide antagonist
AGN211335.
The action of prostamides has been found to involve
mechanisms different from prostanoid FP receptor-mediated
responses in the primate eye. First, the effect of bimatoprost
in the ocular hypertensive monkey model of glaucoma
(Gagliuso et al., 2004) has been shown to be additive to that
of latanoprost, the FP receptor agonist prodrug (Resul et al.,
1997). This fits with the FP-altFP heterodimeric receptor
concept, as divergent secondary Ca
2þ signalling pathways
may translate into an additive effect for prostamides and
prostanoid FP receptor agonists on IOP. A pharmacological
distinction between bimatoprost and latanoprost has also
been made at the clinical level. Glaucomatous human
subjects refractory to latanoprost treatment were found to
be susceptible to bimatoprost, which produced a marked
reduction of IOP (Gandolfi and Cimino, 2003). This fits
particularly well with the FP-altFP heterodimer prostamide
receptor hypothesis as both bimatoprost and latanoprost
would be expected to be active. The recent discovery that
certain single-nucleotide polymorphisms associated with the
FP receptor account for latanoprost insensitivity in
the human eye (Sakurai et al., 2007) may be explained by
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wt FP receptor with an alternative mRNA splicing variant of
the FP receptor becomes insensitive to anionic FP receptor
agonists but retains sensitivity to bimatoprost.
It is now well-established that receptors of the G protein-
coupled receptor variety form heterodimers and that these
can dramatically alter receptor function in terms of ligand
recognition, second messenger signalling and receptor
trafficking (Jordan and Devi, 1999; Breitweiser, 2004; Wilson
et al., 2004; Bulenger et al., 2005; Prinster et al., 2005).
Heterodimerization may create an entirely unique receptor-
binding site (Jordan and Devi, 1999; Wilson et al., 2004).
Prostanoid receptors have also been shown to dimerize;
these occur as an EP1/a2-adrenoceptor heterodimeric com-
plex (McGraw et al., 2006) and dimerization of the IP
receptor and the TPa receptor isoform (Wilson et al., 2004).
In terms of second messenger signalling, the IP/TPa hetero-
dimer confers PGI2-like properties to thromboxane mimetics
in the form of robust TP receptor-mediated cAMP generation
(Wilson et al., 2004). An alternative binding site for
isoprostane E2 was apparently created in the case of IP/TPa,
which may be regarded as analogous to the prostamide
recognition site apparent for the FP-altFP heterodimer.
Isoprostane E2-induced increases in cAMP have been shown
to be dependent on TP receptor expression, but are not
inhibited by the TP antagonist SQ 29548, which sets them
apart from the IP/TPa heterodimer (Wilson et al., 2004).
Formation of a further ligand-binding site is a frequent
occurrence of G protein-coupled receptor dimerization
(Jordan and Devi, 1999; Breitweiser, 2004; Prinster et al.,
2005), and prostanoid receptor heterodimeric complexes
appear to be no exception. For IP/TPa, a unique isoprostane
E2 binding site occurs. In the case of FP-altFP, prostamide
responsiveness is conferred.
Prostaglandin receptor heterodimerization within and
outside the prostanoid receptor classification has already
been shown to have important physiological implications
(Jordan and Devi, 1999; Breitweiser, 2004; Wilson et al.,
2004; Bulenger et al., 2005; Prinster et al., 2005; McGraw
et al., 2006). EP1/a2-adrenoceptor heterodimerization has
an impact on airway tone, in that EP1 receptor stimulation
may reduce a2-adrenoceptor-mediated cAMP formation
and resultant bronchodilatation (McGraw et al., 2006). The
IP/TPa heterodimer may influence the thromboxane/
prostacyclin balance by providing an additional PGI2-like
effect to oppose and limit TPa-mediated effects (Wilson et al.,
2004). Novel ligand-recognition sites emerge as a result of
prostanoid–prostanoid receptor heterodimerization. Thus,
an isoprostane binding site is created by the IP/TPa hetero-
dimers (Wilson et al., 2004). The FP-altFP receptor hetero-
dimers confer prostamide sensitivity, which is lacking in
wild-type FP receptors. It is not easy to rule out the
possibility that the FP-altFP heterodimers are putative
prostamide receptors. It appears that prostamide activity
observed in freshly isolated cells (Gagliuso et al., 2004; Spada
et al., 2005) and tissues (Woodward et al., 2003, 2007; Matias
et al., 2004), such as the feline iris described here, may be
modelled by a recombinant system involving co-expression
of FP and altFP receptors, as suggested by the effects of
bimatoprost.
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